Results 111 to 120 of about 1,615,665 (249)

Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways

open access: yesPulmonary Circulation, 2019
Pulmonary arterial hypertension is a rapidly progressive and often fatal disease. As the pathogenesis of pulmonary arterial hypertension remains unclear, there is currently no good drug for pulmonary arterial hypertension and new therapy is desperately ...
Guosen Yan   +9 more
doaj   +1 more source

Characteristics Associated With Persistent Long COVID Symptoms in Healthcare Personnel Infected With SARS‐CoV‐2 Between August 2022 and May 2024: A Multicenter Cohort Analysis of US Healthcare Personnel

open access: yesAmerican Journal of Industrial Medicine, EarlyView.
ABSTRACT Background Long COVID affects a significant proportion of COVID‐19 survivors. This study examined persistent Long COVID symptoms among healthcare personnel (HCP) and evaluated associations with vaccination, prior SARS‐CoV‐2 infection, underlying health conditions, and demographics.
Eric Kontowicz   +13 more
wiley   +1 more source

Pulmonary arterial hypertension in Saudi Arabia: Patients′ clinical and physiological characteristics and hemodynamic parameters. A single center experience

open access: yesAnnals of Thoracic Medicine, 2014
Aims: The main objective of this study is to describe patients′ clinical characteristics and physiological and hemodynamic parameters at the time of diagnosis in a pulmonary hypertension center in Saudi Arabia.
M M Idrees   +10 more
doaj   +1 more source

Cortisol/cortisone levels and quality of life in individuals with pulmonary arterial hypertension

open access: yesPulmonary Circulation, 2020
Individuals with pulmonary arterial hypertension experience debilitating symptoms and psychological distress which may influence their cortisol regulation. We describe associations between diurnal salivary cortisol/cortisone levels and quality of life in
RMR Tulloh   +4 more
doaj   +1 more source

Understanding pulmonary arterial hypertension

open access: yesNursing Management (Springhouse), 2004
New therapies improve the management of pulmonary arterial hypertension.
openaire   +4 more sources

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

open access: yes, 2016
Elizabeth Ashley Hardin,1 Kelly M Chin2 1Department of Internal Medicine, Division of Cardiology, 2Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA ...
Hardin EA, Chin KM
core  

Heterozygous Variants in LRP1 Cause a Neurodevelopmental Disorder With Congenital Heart Defects

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT LRP1 encodes the low‐density lipoprotein (LDL) receptor‐related protein 1 (LRP1), a transmembrane protein involved in endocytosis and activation of multiple signaling pathways. LRP1 variants have been implicated in the pathogenesis of congenital heart defects (CHD), Alzheimer's disease, and neurodevelopmental disorders (NDD).
Alyssa L. Rippert   +31 more
wiley   +1 more source

Pulmonary hypertension associated with left-sided heart disease.

open access: yes, 2017
Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease ...
Schoch OD   +5 more
core   +1 more source

Systematic Cardiac Phenotyping of Patients With Copy Number Variants in the 15q11.2 Breakpoint 1 to Breakpoint 2 Region: A Retrospective Cohort Study From Nine Pediatric Cardiac Centers

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Microdeletions impacting 15q11.2 breakpoint (BP) 1 to BP2, adjacent to the Prader–Willi critical region, have previously described neuropsychiatric associations, with potential low penetrance presentations of congenital heart disease (CHD) also identified.
Morgan B. Wright   +10 more
wiley   +1 more source

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes

open access: yes, 2013
Soha M Elshaboury,1 Joe R Anderson21College of Pharmacy, University of New Mexico, 2Pharmacy Practice and Internal Medicine, College of Pharmacy and School of Medicine, University of New Mexico, Albuquerque, NM, USAAbstract: Pulmonary arterial ...
Elshaboury SM, Anderson JR
core  

Home - About - Disclaimer - Privacy